Pay in 4 interest-free payments of $5.59 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Lyophilized: Store at 28 C (35.646.4 F)
Orforglipron functions as a partial agonist at the GLP-1 receptor, efficiently coupling to Gs proteins and driving intracellular cyclic adenosine monophosphate (cAMP) accumulation, the canonical signaling pathway responsible for the metabolic effects of GLP-1 receptor activation
Build sustainable movement habits
These are the main differences between the different types of GLP-1 agonists: Semaglutide (Ozempic, Wegovy) Strong anti-inflammatory potential Powerful metabolic benefits and weight loss Longer duration, but higher risk of GI and vestibular side effects Only works on immune cells receptors( not on adipose tissue directly) Tirzepatide (Mounjaro, Zepbound) Works on both GLP-1 and GIP receptors (targeting adipose tissue receptors) Strong anti-inflammatory and insulin-sensitivity effects Significant weight loss Higher likelihood of GI issues in some women Liraglutide (Saxenda) Daily injection Lowest weight loss and inflammation benefits Often gentler on the gut Poorer response for Lipedema in later stages The best choice often depends on: Your gut health Whether you struggle with dizziness or vestibular issues Your appetite levels Your sensitivity to medications Your nutrition status For Lipedema patients, Tirzepatide remains the best therapeutic choice to have a significant benefit on the adipose tissue
